Table 2.
Cumulative Incidence Proportion of Bleeding Events at 30, 60, 90, and 180 Days of Follow‐Up by HAS‐BLED Score
| Time to Bleeding Event | HAS‐BLED Score | ||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ≥4 | |
| (A) Major bleeds, overall | |||||
| 30 d | 0.5% (0.4–0.5%) | 0.5% (0.5–0.6%) | 0.6% (0.5–0.7%) | 0.6% (0.5–0.8%) | 1.1% (0.9–1.4%) |
| 60 d | 0.6% (0.5–0.7%) | 0.7% (0.6–0.8%) | 0.8% (0.8–0.9%) | 0.8% (0.7–1.0%) | 1.7% (1.4–2.0%) |
| 90 d | 0.7% (0.6–0.8%) | 0.9% (0.8–1.0%) | 1.1% (1.0–1.2%) | 1.1% (1.0–1.3%) | 2.3% (2.0–2.7%) |
| 180 d | 0.9% (0.8–1.1%) | 1.3% (1.1–1.4%) | 1.7% (1.5–1.8%) | 2.0% (1.8–2.3%) | 3.4% (3.0–3.9%) |
| (B) Major bleeds, no cancer | |||||
| 30 d | 0.4% (0.3–0.5%) | 0.5% (0.4–0.5%) | 0.5% (0.4–0.6%) | 0.6% (0.5–0.8%) | 1.0% (0.7–1.3%) |
| 60 d | 0.5% (0.4–0.6%) | 0.6% (0.5–0.7%) | 0.7% (0.6–0.8%) | 0.8% (0.6–0.9%) | 1.5% (1.2–1.9%) |
| 90 d | 0.6% (0.5–0.7%) | 0.8% (0.7–0.9%) | 0.9% (0.8–1.0%) | 1.0% (0.9–1.2%) | 2.1% (1.7–2.6%) |
| 180 d | 0.7% (0.6–0.8%) | 1.0% (0.9–1.2%) | 1.3% (1.2–1.5%) | 1.8% (1.6–2.1%) | 3.1% (2.6–3.7%) |
| (C) Major bleeds, cancer only | |||||
| 30 d | 0.9% (0.7–1.3%) | 0.7% (0.6–0.9%) | 0.9% (0.7–1.1%) | 0.7% (0.5–0.9%) | 1.3% (0.9–1.9%) |
| 60 d | 1.3% (1.0–1.7%) | 1.1% (0.8–1.3%) | 1.3% (1.1–1.6%) | 1.0% (0.8–1.3%) | 1.9% (1.4–2.6%) |
| 90 d | 1.7% (1.3–2.1%) | 1.3% (1.1–1.6%) | 1.7% (1.5–2.0%) | 1.3% (1.1–1.7%) | 2.7% (2.1–3.4%) |
| 180 d | 2.4% (1.9–2.9%) | 2.1% (1.8–2.5%) | 2.6% (2.2–2.9%) | 2.5% (2.1–3.0%) | 4.1% (3.3–5.0%) |
| (D) All bleeds, overall | |||||
| 30 d | 1.2% (1.1–1.4%) | 1.4% (1.3–1.5%) | 1.5% (1.4–1.6%) | 1.5% (1.4–1.7%) | 2.5% (2.2–2.9%) |
| 60 d | 1.6% (1.5–1.8%) | 1.9% (1.8–2.1%) | 2.1% (1.9–2.2%) | 2.2% (2.0–2.4%) | 3.7% (3.2–4.2%) |
| 90 d | 1.9% (1.8–2.1%) | 2.4% (2.2–2.5%) | 2.7% (2.6–2.9%) | 3.1% (2.8–3.3%) | 5.0% (4.5–5.6%) |
| 180 d | 2.6% (2.4–2.8%) | 3.4% (3.2–3.6%) | 4.2% (4.0–4.4%) | 5.3% (4.9–5.6%) | 8.0% (7.3–8.7%) |
| (E) All bleeds, no cancer | |||||
| 30 d | 1.0% (0.9–1.2%) | 1.3% (1.1–1.4%) | 1.3% (1.2–1.5%) | 1.6% (1.4–1.8%) | 2.3% (1.9–2.8%) |
| 60 d | 1.4% (1.2–1.5%) | 1.7% (1.6–1.9%) | 1.8% (1.7–2.0%) | 2.1% (1.9–2.4%) | 3.5% (3.0–4.1%) |
| 90 d | 1.6% (1.4–1.8%) | 2.1% (1.9–2.2%) | 2.3% (2.1–2.5%) | 2.9% (2.6–3.2%) | 4.8% (4.2–5.5%) |
| 180 d | 2.1% (2.0–2.3%) | 2.9% (2.7–3.1%) | 3.6% (3.4–3.9%) | 4.8% (4.4–5.2%) | 7.6% (6.8–8.5%) |
| (F) All bleeds, cancer only | |||||
| 30 d | 2.5% (2.0–3.0%) | 1.9% (1.6–2.2%) | 1.9% (1.6–2.1%) | 1.4% (1.2–1.8%) | 2.9% (2.2–3.6%) |
| 60 d | 3.3% (2.7–3.8%) | 2.8% (2.4–3.1%) | 2.8% (2.5–3.2%) | 2.4% (2.1–2.9%) | 4.1% (3.3–4.9%) |
| 90 d | 4.2% (3.6–4.9%) | 3.5% (3.1–3.9%) | 3.8% (3.4–4.2%) | 3.5% (3.0–4.0%) | 5.4% (4.5–6.4%) |
| 180 d | 5.9% (5.2–6.7%) | 5.4% (4.9–6.0%) | 5.8% (5.4–6.3%) | 6.3% (5.6–7.0%) | 8.6% (7.4–9.9%) |
HAS‐BLED indicates Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use.